Skip to main content
  • Singapore's National Defense R&D organization toured the IGH on 16 February 2017

  • Diagnosing, preventing, treating, controlling, eliminating and eradicating diseases of global impact

  • Conducting innovative, world-leading research in Baltimore and overseas

  • Pediatric Infectious Disease Specialist, Dr. Miriam Laufer, to Head Division of Malaria Research.

  • Collaborating with other UMSOM Institutes, Centers, Departments and Programs, and other UMB and University of Maryland System Schools

Institute for Global Health (IGH)

About the IGH

The IGH, established in 2015 at the University of Maryland School of Medicine, is dedicated to improving global health by conducting innovative, world-leading research in Baltimore and around the world.

Led by Founding Director Christopher Plowe, MD, MPH, FASTMH, the institute develops new and improved ways of diagnosing, preventing, treating, controlling, and eradicating diseases of global impact. Currently, these diseases include malaria, Ebola, and vaccine-preventable infectious diseases such as measles. The IGH plans to expand to relevant non-communicable diseases as well.

Singapore's National Defence R&D organization, DSO Singapore, visited UMB on 16 February 2017 to discuss potential collaboration ranging from detection and diagnostics to prophylactics and therapeutics for infectious diseases. Chris Plowe, MD, MPH, FASTM gives a tour of the IGH.

Currently, the IGH includes the Center for Vaccine Development (CVD), directed by Kathleen Neuzil, MD, MPH, who also serves as Deputy Director of IGH, and the Division of Malaria Research, directed by Miriam Laufer, MD. Under the Institute umbrella, CVD continues its 40-year mission to develop, test and deploy vaccines against infectious diseases that will aid the world's underserved population. Former CVD Director Myron M. Levine, MD, DTPH is a senior advisor to the IGH, and Associate Dean for Global Health, Vaccinology and Infectious Diseases.

The new Division of Malaria Research performs the crucial work needed to support global malaria eradication. That work, led by Dr. Laufer, includes developing and deploying innovative tools for improved malaria treatment, prevention and surveillance. The IGH is an instrumental partner in a new international initiative to eliminate malaria in Myanmar.

With more than 30 faculty physicians and scientists, the IGH collaborates with other School of Medicine institutes, centers, departments and programs, as well as other schools on campus, and other entities within the University System of Maryland.


Give to IGH

Christopher V. Plowe, MD, MPH, FASTMH
IGH Founding Director

IGH News

Archived News